Cancer Research UK weighs in on CDF reform

Cancer Research UK (London, U.K.) released its response to a proposal to incorporate the Cancer Drugs Funds into the drug appraisal process of the U.K.'s NICE. The organization supported the proposal, but cited additional considerations for NICE and NHS.

CRUK said NICE decisions should be transparent and that NICE should be flexible in its evidence requirements and timelines for cancer drug approvals, particularly for rare cancers. Under the new program, drugs that require additional evidence before commissioning would receive CDF funding for up to two years, which CRUK said may be insufficient for some diseases. ...